Johnson & Johnson to Participate in the Raymond James 45th Annual Institutional Investors Conference

Johnson & Johnson to Participate in the Raymond James 45th Annual Institutional Investors Conference

February 02, 2024 | Last Trade: US$155.92 3.17 2.08

NEW BRUNSWICK, N.J. / Feb 02, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Raymond James 45^th Annual Institutional Investors Conference on Tuesday, March 5^th, at the JW Marriott Orlando Grande Lakes, Orlando, FL. Ahmet Tezel, Company Group Chairman, MedTech R&D will represent the Company in a session scheduled at 2:15 p.m. (Eastern Time).

This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

The audio webcast replay will be available approximately 48-hrs after the webcast.

Stock Quote

Last Trade:	US$155.92
Daily Change:	3.17 2.08
Daily Volume:	8,210,942
Market Cap:	US$375.770B

June 23, 2025 Johnson & Johnson: IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC) June 15, 2025 Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease June 13, 2025 Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma June 12, 2025 New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia June 11, 2025 Johnson & Johnson: New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis LOAD MORE NEWS

Featured Stock

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE